HOME >> BIOLOGY >> NEWS
Cosmos Studios, MPH Entertainment and the A&E Network announce capture of major scientific discovery on film

Hs Jim Milio, Melissa Peltier and Mark Hufnail have created an inspiring film about a team of young scientists in pursuit of a mystery from a long lost world. The publication of the resulting paper in the journal Science affirms the importance and authenticity of that quest."

"This is A&E's first foray into the hard science and technology genre, an undertaking we would only pursue with partners such as Cosmos Studios and MPH," said Allen Sabinson, A&E's Senior VP of Programming. "We are excited to air "The Lost Dinosaurs of Egypt" documentary on our Network."

MPH cameras rolled as the Penn expedition succeeded in recovering the lost dinosaur sites of German paleontologist Ernst Stromer, who discovered four new species of dinosaurs in Egypt during expeditions from 1910-1914. Stromer uncovered remnants of a Cretaceous-Period eco-system from 100 million years ago, including three Tyrannosaurus-rex-sized predators, the most famous of which, Spinosaurus, sported a five-foot tall sail down its back.

Stromer's Egyptian discoveries were destroyed in an Allied bombing raid during World War II and no official dinosaur expedition had ever returned to this remote part of Egypt until the Penn team's arrival in January of 2000. During a six-week field season, the group recovered nearly 6,000 pounds of dinosaur bones and other fossils to examine. Their research is ongoing.

The fourteen members of the Penn team were led by 30-year-old Penn graduate student Josh Smith and supervised by world-renowned paleontologist, Dr. Peter Dodson. Other members include Penn professor Dr. Robert Giegengack, geologist Dr. Ken Lacovara of Drexel University, Ph.D. candidate in paleontology Matt Lamanna, Ph.D. candidate in geology Jen Smith and Jason Poole, bone preparator for Philadelphias Academy of Natural Sciences. The team discovered startling new facts about this ancient ecosystem that will also be examined in the documentary.

"As a filmmaker, it's t
'"/>

Contact: Steve Syatt
ssyatt@ssapr.com
818-501-0700
Cosmos Studios/MPH Entertainment
31-May-2001


Page: 1 2 3

Related biology news :

1. Canadian Society of Agronomy partners with Plant Management Network
2. NIH launches first center in Nationwide Chemical Genomics Network
3. Land Regeneration Network celebrates first year success
4. NIH establishes Rare Diseases Clinical Research Network
5. University Health Network researchers discover new class of human stem cells
6. Calient Networks chosen as core platform for Optiputer
7. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
8. Networking slows down protein evolution, study reveals
9. Sensor Networks
10. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
11. NCI Awards Hopkins $3.8 Million For Cancer Genetics Network

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: